查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813886

肝病诊断市场规模、份额和趋势分析报告：按诊断技术、疾病、最终用途、地区和细分市场预测，2025-2033 年

Liver Disease Diagnostics Market Size, Share & Trends Analysis Report By Diagnosis Technique, By Disease, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

肝病诊断市场摘要

预计 2024 年全球肝病诊断市场价值将达到 378.5 亿美元，到 2033 年将达到 664 亿美元，2025 年至 2033 年的复合年增长率为 6.39%。

这个市场由创新的诊断工具驱动，这些工具能够早期发现和监测肝病，有助于改善患者的治疗效果。

非侵入性检测方法和分子诊断日益受到重视，这推动了临床领域的需求。这些诊断解决方案正被用于识别肝纤维化、肝硬化、肝炎和其他肝臟相关疾病。推动这一趋势的关键因素之一是主要企业正加强开发针对特定族群（例如孕妇和爱滋病毒感染者）的高灵敏度、快速检测方法。此外，旨在建构精准诊断系统的持续研发工作有望带来及时诊断并改善患者预后。创新诊断方法的采用，以及生活方式的改变（例如增加饮酒量和不良饮食习惯），预计将对肝病诊断市场产生积极影响。

该领域的一项显着进展是FDA于2024年6月核准了Cepheid的Xpert HCV检测和GeneXpert Xpress系统。这项批准标誌着首个照护现场，使医护人员能够在同一诊疗过程中诊断和治疗C型肝炎。此检测只需采集指尖血样，约一小时内即可出结果，并可在多种场所进行，包括物质使用障碍治疗机构、惩教机构、注射器服务项目、医生办公室、急诊科和紧急护理诊所。这项进展表明，肝病护理领域正日益趋向于快速、便捷且以患者为中心的诊断解决方案。

生物标记发现和分子诊断技术的进步显着推动了肝病诊断的发展。次世代定序(NGS) 和液态切片液态生物检体技术的运用，为临床医生提供了更准确、即时的肝病资讯。由于许多肝病通常在无明显症状的情况下进展，这些工具能够更早发现疾病并制定个人化的治疗方法。

在全球范围内，病毒性肝炎、饮酒和非酒精性脂肪性肝病 (NAFLD) 等因素导致的肝病发病率不断上升，进一步推动了市场的成长。此外，人们对肝臟健康的认识不断提高，以及政府改善诊断设施的倡议，也大大促进了市场应用的扩展。此外，向门诊和就地检验的转变也改善了肝病的可及性，从而可以更快地进行干预，并减轻了医疗保健系统的压力。

整体而言，肝病诊断市场的技术创新源自于对更快、更准确、侵入性更低的检测方法的需求。快速照护现场平台和先进分子技术的引入，彻底改变了肝病的检测和管理方式，使及时干预和个人化治疗方案成为可能。此外，人工智慧的整合提升了数据解读和预测能力，而携带式诊断设备则增加了医疗资源匮乏地区的检测可及性。总而言之，这些技术进步有望改善患者的预后，并塑造市场的未来发展轨迹。

目录

第一章调查方法与范围

第二章执行摘要

3. 全球肝病诊断市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场前景。
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
  • 全球肝病诊断市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章全球肝病诊断市场：诊断技术评估与趋势分析

  • 细分仪表板
  • 全球肝病诊断市场诊断技术变化分析
  • 全球肝病诊断市场规模及趋势分析（依诊断技术，2021-2033 年）
  • 影像
  • 实验室检查
  • 内视镜检查
  • 切片检查
  • 其他的

第五章全球肝病诊断市场：疾病评估与趋势分析

  • 细分仪表板
  • 全球肝病诊断市场疾病趋势分析
  • 全球肝病诊断市场规模及趋势分析（按疾病，2021-2033 年）
  • NAFLD
  • NASH
  • 纤维化
  • 肝硬化
  • 肝细胞癌
  • 其他的

第六章：全球肝病诊断市场：最终用途估计与趋势分析

  • 细分仪表板
  • 全球肝病诊断市场最终用途差异分析
  • 全球肝病诊断市场规模与趋势分析（依最终用途，2021-2033 年）
  • 医院
  • 研究所
  • 其他的

第七章肝病诊断市场：区域估计与趋势分析

  • 区域仪表板
  • 市场规模、预测趋势分析，2021-2033年
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 公司/竞争对手分类
  • 战略地图
  • 2023年企业市占率分析
  • 主要认证提供者/计画所有者列表
  • 公司简介/上市公司
    • Abbott
    • F. Hoffmann-La Roche Ltd.
    • Thermo Fisher Scientific Inc.
    • Randox Laboratories Ltd
    • Boston Scientific Corporation
    • Laboratory Corporation of America Holdings
    • Fujifilm Corporation
    • Horiba Medical
    • Siemens Healthcare GmbH
    • Quest Diagnostics
Product Code: GVR-4-68038-693-6

Liver Disease Diagnostics Market Summary

The global liver disease diagnostics market size was valued at USD 37.85 billion in 2024 and is expected to reach USD 66.40 billion by 2033, growing at a CAGR of 6.39% from 2025 to 2033. This market centers on innovative diagnostic tools that enable early detection and monitoring of liver conditions, supporting improved patient outcomes.

The growing emphasis on non-invasive testing methods and molecular diagnostics drives demand across clinical settings. These diagnostic solutions find application in identifying liver fibrosis, cirrhosis, hepatitis, and other liver-related disorders. Key contributors to this trend include the intensified efforts by leading companies to develop sensitive and rapid testing methods tailored for specific demographics, such as pregnant women and individuals living with HIV. Additionally, ongoing research and development aimed at creating accurate diagnostic systems is likely to improve timely diagnoses and patient outcomes. The introduction of innovative diagnostic approaches, along with shifts in lifestyle factors like increased alcohol consumption and poor dietary habits, is also projected to influence the liver disease diagnostics market positively.

A notable advancement in this field is the FDA's approval of the Xpert HCV test and GeneXpert Xpress System by Cepheid in June 2024. This authorization marks the first point-of-care hepatitis C RNA test, allowing healthcare providers to diagnose and treat hepatitis C during the same visit. The test provides results in approximately an hour using a fingertip blood sample and can be conducted in various settings, including substance use disorder treatment facilities, correctional facilities, syringe service programs, doctor's offices, emergency departments, and urgent care clinics. This development exemplifies the growing trend toward rapid, accessible, and patient-centered diagnostic solutions in liver disease care.

Advancements in biomarker discovery and molecular diagnostic methods have greatly advanced liver disease diagnostics. The use of next-generation sequencing (NGS) and liquid biopsy techniques offers clinicians more accurate and real-time understanding of liver conditions. These tools enable early detection of disease and personalized treatment approaches, which are vital because many liver disorders often progress without symptoms.

The increasing rate of liver diseases worldwide, caused by factors such as viral hepatitis, alcohol use, and non-alcoholic fatty liver disease (NAFLD), further drives market growth. Greater awareness about liver health and government efforts to improve diagnostic facilities also significantly contribute to broader market adoption. Moreover, the move toward outpatient care and point-of-care testing improves access, allowing for quicker interventions and easing the pressure on healthcare systems.

Overall, innovation in the liver disease diagnostics market is driven by the need for faster, more accurate, and less invasive testing methods. The introduction of rapid point-of-care platforms and advanced molecular techniques has transformed how liver diseases are detected and managed, enabling timely interventions and personalized treatment plans. Additionally, the integration of artificial intelligence is improving data interpretation and predictive capabilities, while portable diagnostic devices are increasing access to testing in underserved areas. These technological advancements collectively contribute to better patient outcomes and are expected to shape the future trajectory of the market.

Global Liver Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global liver disease diagnostics market on the basis of diagnosis technique, disease, end use and region:

  • Diagnosis Technique Outlook (Revenue, USD Million, 2021 - 2033)
  • Laboratory Tests
  • Imaging
  • Endoscopy
  • Biopsy
  • Others
  • Disease Outlook (Revenue, USD Million, 2021 - 2033)
  • NAFLD
  • NASH
  • Fibrosis
  • Cirrhosis
  • HCC
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Laboratories
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Diagnosis Technique Segment
    • 1.2.2. Disease Segment
    • 1.2.3. End Use Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives
    • 1.10.1. Objective 1
    • 1.10.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. Global Liver Disease Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising Prevalence of Liver Diseases
      • 3.2.1.2. Advancements in Diagnostic Technologies
      • 3.2.1.3. Increasing Awareness and Early Detection
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Advanced Diagnostics
      • 3.2.2.2. Limited Awareness in Developing Regions
    • 3.2.3. Market opportunity analysis
  • 3.3. Global Liver Disease Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Global Liver Disease Diagnostics Market: Diagnosis Technique Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Liver Disease Diagnostics Market Diagnosis Technique Movement Analysis
  • 4.3. Global Liver Disease Diagnostics Market Size & Trend Analysis, by Diagnosis Technique, 2021 to 2033 (USD Million)
  • 4.4. Imaging
    • 4.4.1. Imaging market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5. Laboratory Tests
    • 4.5.1. Laboratory Tests market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6. Endoscopy
    • 4.6.1. Endoscopy market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.7. Biopsy
    • 4.7.1. Biopsy market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Global Liver Disease Diagnostics Market: Disease Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Liver Disease Diagnostics Market Disease Movement Analysis
  • 5.3. Global Liver Disease Diagnostics Market Size & Trend Analysis, by Disease, 2021 to 2033 (USD Million)
  • 5.4. NAFLD
    • 5.4.1. NAFLD market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5. NASH
    • 5.5.1. NASH market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6. Fibrosis
    • 5.6.1. Fibrosis market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7. Cirrhosis
    • 5.7.1. Cirrhosis market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.8. HCC
    • 5.8.1. HCC market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.9. Others
    • 5.9.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Global Liver Disease Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Liver Disease Diagnostics Market End Use Movement Analysis
    • 6.2.1. Global Liver Disease Diagnostics Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 6.3. Hospitals
    • 6.3.1. Hospitals market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4. Laboratories
    • 6.4.1. Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5. Others
    • 6.5.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Liver Disease Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Share Analysis, 2023
  • 8.4. List of Key Certification Providers/Scheme Owners
  • 8.5. Company Profiles/Listing
    • 8.5.1. Abbott
      • 8.5.1.1. Company overview
      • 8.5.1.2. Financial performance
      • 8.5.1.3. Product benchmarking
      • 8.5.1.4. Strategic initiatives
    • 8.5.2. F. Hoffmann-La Roche Ltd.
      • 8.5.2.1. Company overview
      • 8.5.2.2. Financial performance
      • 8.5.2.3. Product benchmarking
      • 8.5.2.4. Strategic initiatives
    • 8.5.3. Thermo Fisher Scientific Inc.
      • 8.5.3.1. Company overview
      • 8.5.3.2. Financial performance
      • 8.5.3.3. Product benchmarking
      • 8.5.3.4. Strategic initiatives
    • 8.5.4. Randox Laboratories Ltd
      • 8.5.4.1. Company overview
      • 8.5.4.2. Financial performance
      • 8.5.4.3. Product benchmarking
      • 8.5.4.4. Strategic initiatives
    • 8.5.5. Boston Scientific Corporation
      • 8.5.5.1. Company overview
      • 8.5.5.2. Financial performance
      • 8.5.5.3. Product benchmarking
      • 8.5.5.4. Strategic initiatives
    • 8.5.6. Laboratory Corporation of America Holdings
      • 8.5.6.1. Company overview
      • 8.5.6.2. Financial performance
      • 8.5.6.3. Product benchmarking
      • 8.5.6.4. Strategic initiatives
    • 8.5.7. Fujifilm Corporation
      • 8.5.7.1. Company overview
      • 8.5.7.2. Financial performance
      • 8.5.7.3. Product benchmarking
      • 8.5.7.4. Strategic initiatives
    • 8.5.8. Horiba Medical
      • 8.5.8.1. Company overview
      • 8.5.8.2. Financial performance
      • 8.5.8.3. Product benchmarking
      • 8.5.8.4. Strategic initiatives
    • 8.5.9. Siemens Healthcare GmbH
      • 8.5.9.1. Company overview
      • 8.5.9.2. Financial performance
      • 8.5.9.3. Product benchmarking
      • 8.5.9.4. Strategic initiatives
    • 8.5.10. Quest Diagnostics
      • 8.5.10.1. Company overview
      • 8.5.10.2. Financial performance
      • 8.5.10.3. Product benchmarking
      • 8.5.10.4. Strategic initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviation
  • Table 3. U.S. Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 4. U.S. Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 5. U.S. Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 6. North America Liver Disease Diagnostics market, by region, 2021 to 2033 (USD Million)
  • Table 7. North America Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 8. North America Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 9. North America Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 10. Canada Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 11. Canada Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 12. Canada Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 13. Mexico Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 14. Mexico Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 15. Mexico Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 16. Europe Liver Disease Diagnostics market, by region, 2021 to 2033 (USD Million)
  • Table 17. Europe Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 18. Europe Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 19. Europe Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 20. UK Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 21. UK Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 22. UK Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 23. Germany Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 24. Germany Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 25. Germany Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 26. France Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 27. France Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 28. France Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 29. Italy Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 30. Italy Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 31. Italy Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 32. Spain Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 33. Spain Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 34. Spain Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 35. Denmark Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 36. Denmark Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 37. Denmark Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 38. Sweden Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 39. Sweden Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 40. Sweden Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 41. Norway Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 42. Norway Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 43. Norway Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 44. Asia Pacific Liver Disease Diagnostics market, by region, 2021 to 2033 (USD Million)
  • Table 45. Asia Pacific Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 46. Asia Pacific Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 47. Asia Pacific Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 48. Japan Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 49. Japan Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 50. Japan Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 51. China Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 52. China Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 53. China Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 54. India Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 55. India Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 56. India Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 57. Australia Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 58. Australia Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 59. Australia Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 60. South Korea Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 61. South Korea Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 62. South Korea Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 63. Thailand Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 64. Thailand Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 65. Thailand Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 66. Latin America Liver Disease Diagnostics market, by region, 2021 to 2033 (USD Million)
  • Table 67. Latin America Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 68. Latin America Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 69. Latin America Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 70. Brazil Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 71. Brazil Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 72. Brazil Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 73. Argentina Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 74. Argentina Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 75. Argentina Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 76. MEA Liver Disease Diagnostics market, by region, 2021 to 2033 (USD Million)
  • Table 77. MEA Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 78. MEA Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 79. MEA Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 80. South Africa Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 81. South Africa Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 82. South Africa Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 83. Saudi Arabia Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 84. Saudi Arabia Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 85. Saudi Arabia Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 86. UAE Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 87. UAE Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 88. Kuwait Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 89. Kuwait Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 90. Kuwait Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Liver disease diagnostics: Market outlook
  • Fig. 9 Liver disease diagnostics: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Liver disease diagnostics market driver impact
  • Fig. 15 Liver disease diagnostics market restraint impact
  • Fig. 16 Liver disease diagnostics market strategic initiatives analysis
  • Fig. 17 Liver disease diagnostics market: disease movement analysis
  • Fig. 18 Liver disease diagnostics market: disease outlook and key takeaways
  • Fig. 19 NAFLD market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 20 NASH market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 21 Fibrosis market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 22 Cirrhosis market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 23 HCC market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 24 Others market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 25 Liver disease diagnostics market: Diagnosis technique movement analysis
  • Fig. 26 Liver disease diagnostics market: Diagnosis technique outlook and key takeaways
  • Fig. 27 Imaging market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 28 Laboratory tests market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 29 Endoscopy market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 30 Biopsy market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 31 Others market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 32 Liver disease diagnostics market: End use movement analysis
  • Fig. 33 Liver disease diagnostics market: End use outlook and key takeaways
  • Fig. 34 Hospitals market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 35 Laboratories market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 36 Others market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 37 Global liver disease diagnostics market: Regional movement analysis
  • Fig. 38 Global liver disease diagnostics market: Regional outlook and key takeaways
  • Fig. 39 North America market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 40 US market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 41 Canada market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 42 Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 43 Europe market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 44 UK market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 45 Germany market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 46 France market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 47 Italy market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 48 Spain market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 49 Sweden market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 50 Norway market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 51 Denmark market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 52 Asia Pacific market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 53 Japan market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 54 China market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 55 India market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 56 Australia market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 57 Thailand market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 58 South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 59 Latin America market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 60 Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 61 Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 62 Middle East and Africa market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 63 Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 64 South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 65 UAE market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 66 Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)